Research and Reports in Immunology

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Abstract - Research and Reports in Immunology (2021) Volume 4, Issue 5

Quadrivalent and nonavalent HPV vaccine: Ovarian safety research.

 Human papillomavirus (HPV) vaccination may prevent up to 90% of oncogenic HPV infection. Quadrivalent and 9-valent vaccines and HPV testing are replacing the Papanicolaou cervical screening programme to reduce cervical cancer in Australia, which is now mostly confined to women not accessing regular screening. HPV vaccine marketing, licensing and advisory body statements of ovarian safety have followed case series of premature ovarian insufficiency (POI) in vaccine recipients.

Author(s): Deirdre Little

Abstract Full Text PDF

Get the App